Press Release: Heart Metabolics : Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy

-- Company Appoints William Daly as Chief Executive Officer and Gregory M. Ayers, M.D., Ph.D., as Chief Medical Officer DUBLIN, April 15, 2015 /PRNewswire/ -- Heart Metabolics Limited, a biotechnology company focused on the development of drugs for orphan diseases including...